Opus Genetics, Inc. 10-Q

Item 5. Other Information None. Item 6. Exhibits EXHIBIT NUMBER ​ DESCRIPTION OF DOCUMENT 10.1 Third Lease Amendment, dated as of September 9, 2021, by and between the Company and Duke & Duke 31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 33 Index Ocuphire Pharma, Inc. Form 10-Q SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: November 12, 2021 Ocuphire Pharma, Inc. By: /s/ Mina Sooch Mina Sooch Chief Executive Officer (Principal Executive Officer) By: /s/ Amy Rabourn Amy Rabourn Vice President Finance (Principal Financial Officer) 34